{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:01:30Z","timestamp":1781218890375,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Scientific and Technological Project of Henan Province","award":["NO.242102311033"],"award-info":[{"award-number":["NO.242102311033"]}]},{"name":"the Major Project of Guangzhou National Laboratory, the Scientific and Technological Project of Henan Province, the Independent Project of Shanghai Sci-Tech Inno Centre for Infection & Immunity"},{"name":"the Independent Project of Shanghai Sci-Tech Inno Centre for Infection & Immunity","award":["SSIII-2024B01, SSIII-202404"],"award-info":[{"award-number":["SSIII-2024B01, SSIII-202404"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rifampicin-resistant tuberculosis (RR-TB) poses a great threat to global health. Increasing evidence of novel regimens in trial settings has risen, but the combinations of oral shorter regimens have not been optimised. An evaluation of the efficacy and safety of short-term regimens utilizing various drug combinations is essential across different settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      INSPIRE TB is a pragmatic, multicentre, randomised, controlled, non-inferiority open-label trial to evaluate novel regimens in pulmonary RR-TB patients of 16\u201375 years old with or without fluoroquinolone resistance. Before randomisation, an individualized assessment is conducted, considering drug susceptibility, contradictions, tolerance. Eligible participants are randomised based on fluoroquinolone susceptibility results from the Xpert MTB\/XDR assay. Participants susceptible to fluoroquinolones are randomised to receive either one of seven different nine-month oral regimens or a nine-month standard-of-care regimen as the control. The experimental arms are five-drug regimens, each consisting of five agents selected from the following: bedaquiline, linezolid, a fluoroquinolone, cycloserine, clofazimine and pyrazinamide. Fluoroquinolone-resistant participants are randomised to either a 9-month oral regimen (bedaquiline, cycloserine, clofazimine, linezolid and pyrazinamide), or a 20-month conventional regimen as control in a 1:1 ratio. The primary outcome is the proportion of participants with a favourable outcome (two negative culture for\n                      <jats:italic>Mycobacterium Tuberculosis<\/jats:italic>\n                      , the latest sample collected between month 21 and 23) at 21 months after randomisation in the modified intention-to-treat population, measured in fluoroquinolone-susceptible and fluoroquinolone-resistant participants respectively. A sample size of 832 fluoroquinolone-susceptible RR-TB patients and 234 fluoroquinolone-resistant RR-TB patients afford 80% power to establish non-inferiority with a non-inferiority margin of 10% at a one-sided \u03b1 level of 2.5%. The type I error will be controlled with a fixed-sequence approach.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Identifying safer and effective short regimens remains an obstacle for drug-resistant tuberculosis and more treatment options are needed to benefit patients from different countries and settings to reduce disease burden. The INSPIRE TB study hopes to provide robust evidence on various options of safer and effective 9-month oral regimens for RR-TB in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trail registration<\/jats:title>\n                    <jats:p>ClinicalTrial.gov, NCT05081401. Registered on October 18, 2021; the record was lastupdated for study protocol version 6.0, on 06 April 2025.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-13017-y","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:46:46Z","timestamp":1773748006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Innovating shorter, all-oral, precise, individualized treatment regimen for rifampicin-resistant tuberculosis (INSPIRE TB): study protocol for a pragmatic randomised controlled trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Yilin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajiao","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiqin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the INSPIRE TB study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"13017_CR1","volume-title":"Global tuberculosis report 2023","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization; 2023."},{"key":"13017_CR2","doi-asserted-by":"publisher","DOI":"10.54394\/CJQU6666","volume-title":"Global tuberculosis report 2024","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization; 2024."},{"key":"13017_CR3","volume-title":"Global tuberculosis report 2025","author":"World Health Organization","year":"2025","unstructured":"World Health Organization. Global tuberculosis report 2025. Geneva: World Health Organization; 2025."},{"key":"13017_CR4","unstructured":"World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization. 2022;2022."},{"issue":"13","key":"13017_CR5","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","volume":"380","author":"AJ Nunn","year":"2019","unstructured":"Nunn AJ, Phillips PPJ, Meredith SK, Chiang C-Y, Conradie F, Dalai D, et al. A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2019;380(13):1201\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1811867.","journal-title":"N Engl J Med"},{"issue":"10","key":"13017_CR6","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020;382(10):893\u2013902. https:\/\/doi.org\/10.1056\/NEJMoa1901814.","journal-title":"N Engl J Med"},{"issue":"10366","key":"13017_CR7","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1016\/s0140-6736(22)02078-5","volume":"400","author":"RL Goodall","year":"2022","unstructured":"Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, Bronson G, et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial. Lancet (London England). 2022;400(10366):1858\u201368. https:\/\/doi.org\/10.1016\/s0140-6736(22)02078-5.","journal-title":"Lancet (London England)"},{"key":"13017_CR8","doi-asserted-by":"publisher","unstructured":"Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Abubakirov A, Baudin E, et al. Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis. N Engl J Med. 2025;392(5). https:\/\/doi.org\/10.1056\/NEJMoa2400327.","DOI":"10.1056\/NEJMoa2400327"},{"key":"13017_CR9","doi-asserted-by":"publisher","unstructured":"Zhang Y, Zhang J, Cui P, Zhang Y, Zhang W. Identification of novel efflux proteins Rv0191, Rv3756c, Rv3008, and Rv1667c involved in pyrazinamide resistance in mycobacterium tuberculosis. Antimicrob Agents Chemother. 2017;61(8). https:\/\/doi.org\/10.1128\/aac.00940-17.","DOI":"10.1128\/aac.00940-17"},{"key":"13017_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2017.1","author":"S Zhang","year":"2017","unstructured":"Zhang S, Chen J, Shi W, Cui P, Zhang J, Cho S, et al. Mutation in clpC1 encoding an ATP-dependent ATPase involved in protein degradation is associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infections. 2017. https:\/\/doi.org\/10.1038\/emi.2017.1.","journal-title":"Emerg Microbes Infections"},{"key":"13017_CR11","unstructured":"Commission GONH, General Office of the National Health Commission Circular on the issuance of technical specifications for tuberculosis prevention and control in China. (2020). 2020https:\/\/doi.org\/https:\/\/tb.chinacdc.cn\/ggl\/202004\/P020200414515703939844.pdf"},{"key":"13017_CR12","unstructured":"World Health Organization. Manual for selection of molecular WHO-recommended rapid diagnostic tests for detection of tuberculosis and drug-resistant tuberculosis. Geneva: World Health Organization. 2022;2022."},{"key":"13017_CR13","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment. 2022 update ed. Geneva: World Health Organization. 2022;2022."},{"key":"13017_CR14","unstructured":"World Health Organization. Key updates to the treatment of drug-resistant tuberculosis: rapid communication, June 2024. Geneva: World Health Organization. 2024;2024."},{"issue":"6","key":"13017_CR15","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1093\/cid\/ciae388","volume":"79","author":"C Padmapriyadarsini","year":"2024","unstructured":"Padmapriyadarsini C, Oswal VS, Jain CD, Mariappan MV, Singla N, Kumar S, et al. Effectiveness and Safety of Varying Doses of Linezolid With Bedaquiline and Pretomanid in Treatment of Drug-Resistant Pulmonary Tuberculosis: Open-Label, Randomized Clinical Trial. Clin Infect Dis. 2024;79(6):1375\u201385. https:\/\/doi.org\/10.1093\/cid\/ciae388.","journal-title":"Clin Infect Dis"},{"key":"13017_CR16","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment. Geneva: World Health Organization. 2020;2020."},{"issue":"3","key":"13017_CR17","doi-asserted-by":"publisher","first-page":"E938","DOI":"10.1093\/cid\/ciac528","volume":"76","author":"C Padmapriyadarsini","year":"2023","unstructured":"Padmapriyadarsini C, Vohra V, Bhatnagar A, Solanki R, Sridhar R, Anande L, et al. Bedaquiline, Delamanid, Linezolid, and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis. Clin Infect Dis. 2023;76(3):E938\u201346. https:\/\/doi.org\/10.1093\/cid\/ciac528.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"13017_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S2213-2600(23)00389-2","volume":"12","author":"B-T Nyang\u2019wa","year":"2024","unstructured":"Nyang\u2019wa B-T, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial. Lancet Respiratory Med. 2024;12(2):117\u201328. https:\/\/doi.org\/10.1016\/S2213-2600(23)00389-2.","journal-title":"Lancet Respiratory Med"},{"issue":"25","key":"13017_CR19","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","volume":"387","author":"B-T Nyang\u2019wa","year":"2022","unstructured":"Nyang\u2019wa B-T, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022;387(25):2331\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2117166.","journal-title":"N Engl J Med"},{"key":"13017_CR20","doi-asserted-by":"publisher","DOI":"10.2471\/B09458","volume-title":"WHO consolidated guidelines on tuberculosis: module 4: treatment and care","author":"World Health Organization","year":"2025","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment and care. Geneva: World Health Organization; 2025. 2025-03-14."},{"issue":"9","key":"13017_CR21","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa2119430","volume":"387","author":"F Conradie","year":"2022","unstructured":"Conradie F, Bagdasaryan TRR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2022;387(9):810\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2119430.","journal-title":"N Engl J Med"},{"key":"13017_CR22","doi-asserted-by":"publisher","unstructured":"Berry C, du Cros P, Fielding K, Gajewski S, Kazounis E, McHugh TD, et al. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis. Trials. 2022;23(1). https:\/\/doi.org\/10.1186\/s13063-022-06331-8.","DOI":"10.1186\/s13063-022-06331-8"},{"key":"13017_CR23","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents. Geneva: World Health Organization. 2022;2022."},{"issue":"2","key":"13017_CR24","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1093\/cid\/ciad767","volume":"79","author":"T Crocker-Buque","year":"2024","unstructured":"Crocker-Buque T, Lachenal N, Narasimooloo C, Abdrasuliev T, Parpieva N, Tigay Z, et al. Pregnancy Outcomes in Multidrug-Resistant Tuberculosis in TB-PRACTECAL. Clin Infect Dis. 2024;79(2):569\u201370. https:\/\/doi.org\/10.1093\/cid\/ciad767.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"13017_CR25","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/cid\/ciad445","volume":"78","author":"I Lotia Farrukh","year":"2024","unstructured":"Lotia Farrukh I, Lachenal N, Adenov MM, Ahmed S, Algozhin Y, Coutisson S, et al. Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs. Clin Infect Dis. 2024;78(1):144\u20138. https:\/\/doi.org\/10.1093\/cid\/ciad445.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13017-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13017-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13017-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T01:53:05Z","timestamp":1776995585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13017-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13017"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13017-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial has received ethical approval from Ethics Advisory Group of Huashan Hospital, Fudan University (approval number KY2021\u2013878). Written informed consent must be obtained from all participants prior to screening and randomisation. Any amendments to the protocol or consent materials are reviewed and approved by Ethics Advisory Group of Huashan Hospital before they are submitted to local site authorities for approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"828"}}